Abstract
Thalidomide, the drug that caused a worldwide epidemic of serious birth defects in the late 1950s and early 1960s, was recently approved by the US Food and Drug Administration (FDA) for use in treating the skin disease erythema nodosum leprosum, a complication of leprosy. The drug has also shown promise in the treatment of other serious diseases. If thalidomide is eventually approved for use in the US and other countries for treatment of diseases more prevalent than erythema nodosum leprosum, or if use of the drug for non-approved indications becomes widespread, hundreds of thousands of women with childbearing ability could be treated. If this should happen, can we prevent another epidemic of birth defects?
In an effort to prevent fetal exposures to thalidomide, the FDA mandated a comprehensive programme to regulate prescription, dispensing and use of the drug. The programme is designed to require registration of all participating pre-scribers, pharmacies and patients. It also requires use of effective methods of contraception and periodic pregnancy testing of all patients with childbearing ability during treatment. Prescribers are directed to counsel both female and male patients on the risks, benefits and proper use of the drug, as well as on the proper use of contraceptives during treatment. The patient is required to sign an informed consent form before beginning treatment. Prescription and dispensing of thalidomide will be tightly controlled. A thalidomide registry will monitor prescription, dispensing and use of the drug, and will investigate all reported fetal exposures.
This mandatory, but untested, programme promises to be effective at preventing fetal exposures to thalidomide, provided that patients, prescribers and pharmacists comply with all of its provisions. However, even if the programme proves to be successful in the US, there is concern that thalidomide may eventually be widely used in countries that may not require such stringent controls. In Brazil, where thalidomide is commercially available for treatment of leprosy patients, 33 cases of thalidomide embryopathy have already been reported in the literature. Even in countries that may tightly regulate the distribution and use of thalidomide, some patients may obtain the drug through black market sources. Should these events occur, many cases of thalidomide-induced birth defects could appear. Therefore, there is a need to develop nonteratogenic analogues of thalidomide that can provide effective treatment for erythema nodosum leprosum and other serious conditions without increasing the potential for another epidemic of thalidomide-related birth defects.
Similar content being viewed by others
References
Wiedemann HR. Hinweis auf eine derzeitige Häufung hypound aplastischer Fehlbildungen der Gliedermassen. Med Welt 1961 Sep 16; 37: 1863–6
McBride WG. Thalidomide and congenital abnormalities. Lancet 1961 Dec 16; II: 1358
Smithells RW. Thalidomide and malformations in Liverpool. Lancet 1962 Jun 16; I: 1270–3
Lenz W. Fragen aus der Praxis: Kindliche Missbildungen nach Medikament Einnahme während der Gravidität? Dtsch Med Wochenschr 1961; 86: 2555–6
Burley D. Is thalidomide to blame? BMJ 1961; 1: 130
Fullerton PM, Kremer M. Neuropathy after intake of thalidomide (Distaval). BMJ 1961; 2: 855–8
Lenz W. A short history of thalidomide embryopathy. Teratology 1988 Sep; 38(3): 203–15
D’Arcy PF, Griffin JP. Thalidomide revisited. Adverse Drug React Toxicol Rev 1994; 13(2): 65–76
Kelsey FO. Thalidomide update: regulatory aspects. Teratology 1988 Sep; 38(3): 221–6
Shepard TH. Catalog of teratogenic agents. 8th ed. Baltimore (MD): Johns Hopkins University Press, 1995
Smithells RW, Newman CGH. Recognition of thalidomide defects. J Med Genet 1992 Oct; 29(10): 716–23
Jakeman P, Smith WCS. Thalidomide in leprosy reaction. Lancet 1994 Feb 19; 343(8895): 432–3
Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf 1992 Mar–Apr; 7(2): 116–34
D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994 Apr 26; 91(9): 4082–5
Friedman JM, Polifka JE. Teratogenic effects of drugs: a resource for clinicians (TERIS). Baltimore (MD): Johns Hopkins University Press, 1994
Dermatologic Drugs Advisory Committee. Open public hearing on NDA 18–662 Accutane (isotretinoin capsules) [transcript]. Rockville (MD): FDA Center for Drug Evaluation and Research, 1988
Stern RS. When a uniquely effective drug is teratogenic: the case of isotretinoin. N Engl J Med 1989 Apr 13; 320(15): 1007–9
Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995 Jul 13; 333(2): 101–6
Holmes SC, Bankowska U, Mackie RM. The prescription of isotretinoin to women: is every precaution taken? Br J Dermatol 1998 Mar; 138(3): 450–5
Chan A, Keane RJ, Hanna M, et al. Terminations of pregnancy for exposure to oral retinoids in South Australia, 1985–1993. Aust NZ J Obstet Gynaecol 1995; 35(4): 422–6
Pastuzak A, Koren G, Rieder MJ. Use of the retinoid pregnancy prevention program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate. Reprod Toxicol 1994 Jan–Feb; 8(1): 63–8
System for Thalidomide Education and Prescribing Safety (STEPS) [prescriber folder]. Warren (NJ): Celgene Corp., 1998
Castilla EE, Ashton-Prolla P, Barreda-Mejia E, et al. Thalidomide, a current teratogen in South America. Teratology 1996 Dec; 54(6): 273–7
Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997 May 22; 336(21): 1487–93
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lary, J.M., Daniel, K.L., Erickson, J.D. et al. The Return of Thalidomide. Drug-Safety 21, 161–169 (1999). https://doi.org/10.2165/00002018-199921030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199921030-00002